We read with great interest the report of Zong et al.
1 in a recent issue of Leukemia dealing with the role of P-glycoprotein in imatinib resistance in vitro and in vivo. Using a transposonbased vector system we previously provided clear evidence that the specific knockdown of PgP using small interfering RNA (siRNA) resensitized imatinib-resitant cell lines to the growth inhibitory and cytotoxic effects of imatinib.
2 Other groups underlined the importance of PgP for imatinib transport by showing that it eliminates imatinib from the intracellular space at concentrations ranging from 0.5 to 3 mg/ml.
3 Although recognizing their impressive in vivo data, the animal model does not reflect the situation in malignant diseases, as under the latter condition the cancerous cells in general acquired resistance under chemotherapy and therefore express very high levels pf PgP. In contrast, the authors used stem cells of wildtype animals expressing 'physiologic' levels of Mdr1a/Mdr1b and compared these cells with cells from knockout mice (Mdr1a/Mdr1b-null). Moreover, the controversial in vitro data might also reflect different experimental approaches, as an isolated overexpression as carried out by Ferrao et al 4 or by Zong et al.
1 might be far more artificial when compared to the use of cells which upregulated PgP due to long-term culture in the presence of low-dose doxorubicin (which in our opinion more closely reflects the in vivo situation of acquiered drug resistance). We would even argue that the genetic modification using retroviral vectors might substantionally modify genetic programs by insertional mutagenesis. Finally, it is in our opinion critical that the authors used a model employing the mouse homologue of the human MDR1 gene. Thus, the same sensitivity to Glivec might also be due to a different substrate affinity to the mouse homologue.
Considering these points we feel that our data using the specificity of an siRNA approach strongly argue for the participation of PgP in chemoresistance to the cytotoxic effects of imatinib. The letter by Rumpold et al. 1 raises several objections to our conclusion that inhibition of P-glycoprotein (P-gp) is not likely to improve the response to imatinib in chronic myelogenous leukemia (CML). Their argument is in part based on their previous results showing that downregulation of P-gp expression in K562 cells sensitized the cells to imatinib treatment in vitro.
2 However, our data in K562 cells 3 and that of Ferrao et al. 4 show that overexpression of P-gp does not confer significant resistance to imatinib in K562 cells. Rumpold et al. argue that this discrepancy could be due to potential differences in the level of P-gp expression in their doxorubicin-selected K562 cells versus our K562 cells that were transduced with an MDR1 retroviral vector. While this may be true, it is unclear how the levels of P-gp expression in any of these cell lines compare to that seen in primary CML stem cells. For this reason, we used an in vivo model of murine CML in which imatinib resistance was assessed in stem cells from P-gp null mice. Our data showed that loss of P-gp expression had no effect on imatinib responses.
3 Rumpold et al. argue that CML cells from patients may express higher levels of P-gp than in the mouse model due to the effects of prior drug therapy in patients. However, a previous clinical study reported that low levels of MDR1 gene expression in CML blast cells was not a predictor of response to imatinib in patients with CML blast crisis.
5 In addition, a recent report showed that there was no significant difference in expression of P-gp in bone marrow cells from 15 patients who were imatinib responders versus 15 nonresponders.
6 Furthermore, we treated mice continuously for up to 5 weeks with imatinib, so there is no a priori reason to believe that selection for high P-gp expression would not also occur in the mouse model system. Lastly, Rumpold et al. question whether the murine Mdr1-like gene products may differ from the human P-gp with regard to imatinib efflux capacity. While there are no data to directly compare
